BREAKING🔔 The 14th paper from G2P-Japan🇯🇵 is out at Cell Host & Microbe @cellhostmicrobe. #Omicron BA.2.75 (aka #Centaurus) seems to be more contagious than BA.5 and more pathogenic than the original BA.2. Please RT. 1/16 cell.com/cell-host-micr…
BA.2.75, emerged in India🇮🇳, is classified as VOC-LUM (variant of concern linage under monitoring) by WHO on July 7. Here we elucidated the transmissibility, sensitivity to antiviral immunity & drugs, and intrinsic pathogenicity of BA.2.75. 2/16 who.int/activities/tra…
BA.2.75 is a descendant of BA.2. However, BA.2.75 is phylogenetically different from BA.5, the currently predominant BA.2 descendant. BA.2.75 spike bears nine substitutions, but only a substitution is shared with BA.5 spike. 3/16
First, our mathematical/statistical analysis revealed that the effective reproduction number ("Re" in the figure) of BA.2.75 is greater than that of BA.5. 4/16
Second, we performed neutralization assay. we showed that:
1⃣ Resistance to 3rd-dose vaccine sera: BA.2.75 = BA.2. 5/16
Antiviral activity of three drugs, Remdesivir, Molnupiravir (EIDD-1931) and Paxlovid (Nirmatrelvir) against BA.2.75 was also evaluated. All 3 drugs were effective against BA.2.75. 12/16
We solved the structure of BA.2.75 spike by cryo-electron microscopy and showed how BA.2.75 spike exhibits very high affinity to human ACE2 receptor. 13/16
Like BA.5 spike, BA.2.75 spike is highly fusogenic than BA.2. 14/16
Using clinical isolates of BA.2, BA.2.75, BA.2 & Delta and a hamster model, we demonstrated that the intrinsic pathogenicity of BA.2.75 is comparable to that of BA.5 but is greater than that of the original BA.2. 15/16
▶️ Our multiscale investigations suggest that BA.2.75 acquired virological properties independently of BA.5, and the potential risk of BA.2.75 to global health may be greater than that of BA.5. 16/16
• • •
Missing some Tweet in this thread? You can try to
force a refresh
BREAKING🔔 A new study from G2P-Japan🇯🇵, led by Keiya @Keiya717, is out at @biorxivpreprint. We assessed the humoral immunity induced by JN.1 mRNA vaccines against a broad range of SARS-CoV-2 variants including JN.1, KP.3.1.1 & XEC. Please repost🔥 1/ biorxiv.org/content/10.110…
In this study, we used 2 mRNA vaccines, one is from Pfizer/BioNTech🇺🇸🇩🇪, while another is from Daiichi-Sankyo🇯🇵. The good news is that there are no significant differences between them and both broadly neutralized a variety of SARS-CoV-2 including JN.1, KP.3.1.1 and XEC. 2/
But there are two scientific interests.
First, compared to our recent study using JN.1 and KP.3.3 breakthrough (i.e. natural) infection sera, antiviral humoral immunity against KP.3 and XEC was weakly induced. However, JN.1 mNRA vaccine can. Why🤔?? 3/
BREAKING🔔 A new study from G2P-Japan🇯🇵, led by Yu in my lab, is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 #XEC. Please repost🔥 1/ biorxiv.org/content/10.110…
Compared with KP.3, #XEC harbors two spike substitutions, S:T22N and S:F59S. Recombination analysis by Shusuke @KawakuboShusuke showed that XEC is a recombinant lineage of KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3) with a breakpoint at genomic position 21,738–22,599. 2/
Transmissibility/fitness (Re):
Molecular phylogenetic-epidemic dynamics modeling led by Jumpei @jampei2 and Kaho showed that the Re of #XEC is greater than that of KP.3.1.1, the most predominant variant in the world. 3/
BREAKING🔔 Here I want to quickly report our new results from G2P-Japan🇯🇵 before the preprint publication. We have elucidated the virological characteristics of SARS-CoV-2 KP.3.1.1 - a progeny of JN.1. Please RT🔥 1/
Cf.1 A new one, KP.2 (JN.1.11.1.2), has been already elucidated. 2/